摘要
目的 观察缩泉丸合水陆二仙丹治疗慢性肾小球肾炎(Chronic glomerulonephritis,CGN)患者的临床疗效及对其肾功能的影响。方法 选取2021年11月—2024年11月在西安交通大学第二附属医院接受治疗的120例CGN患者,按随机数字表法分为对照组和观察组,每组60例。对照组采用缬沙坦胶囊干预,观察组在对照组治疗的基础上,联合缩泉丸合水陆二仙丹进行干预,均治疗2个月。观察比较两组患者的临床疗效、不良反应情况,治疗前后中医证候积分、肾功能指标[尿素氮(Blood urea nitrogen,BUN)、血肌酐(Serum creatinine,SCr)、24 h尿蛋白(24-hour urine protein,24 h-Upro)]、氧化应激指标[活性氧(Reactive oxygen species,ROS)、超氧化物歧化酶(Superoxide dismutase,SOD)和丙二醛(Malondialdehyde,MDA)]及内皮功能指标[血清内皮素-1(Endothelin-1,ET-1)、一氧化氮(Nitric oxide,NO)]。结果 治疗后观察组临床总有效率95.00%(57/60)明显高于对照组83.33%(50/60),差异有统计学意义(P<0.05)。治疗后两组患者中医证候积分均较治疗前降低,差异有统计学意义(P<0.05);且观察组中医证候积分较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者肾功能指标表达水平均较治疗前降低,差异有统计学意义(P<0.05);且观察组肾功能指标表达水平较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者ROS、MDA较治疗前降低,SOD较治疗前升高,差异有统计学意义(P<0.05);且观察组ROS、MDA较对照组明显降低,SOD较对照组明显升高,差异有统计学意义(P<0.05)。治疗后两组患者ET-1较治疗前降低,NO较治疗前升高,差异有统计学意义(P<0.05);且观察组ET-1较对照组明显降低,NO较对照组明显升高,差异有统计学意义(P<0.05)。治疗期间,观察组不良反应发生率5.00%(3/60)明显低于对照组16.67%(10/60),差异有统计学意义(P<0.05)。结论 缩泉丸合水陆二仙丹联合西医治疗可改善肾气不固型CGN患者的中医证候及肾功能,其机制可能与抗氧化应激、调节内皮功能及多靶点协同作用相关,且安全性更高。
Objective To explore the clinical efficacy of Suoquan Pills and Shuilu Erxian Pills for chronic glomerulonephritis(CGN)and the combined treatment's effects on patients'renal function.Methods A total of 120 CGN patients treated at The Second Affiliated Hospital of Xi'an Jiaotong University from November 2021 to November 2024 were selected and divided into a control group and an observation group by the random number table method,with 60 cases in each group.Both groups received valsartan capsules,while the observation group additionally received Suoquan Pills and Shuilu Erxian Pills.After treatment for 2 months,clinical efficacy and adverse reactions were compared between the two groups,as well as aspects below before and after treatment:TCM syndrome scores,renal function indicators[blood urea nitrogen(BUN),serum creatinine(SCr),24-hour urine protein(24 h-Upro)],oxidative stress indicators[reactive oxygen species(ROS),superoxide dismutase(SOD),and malondialdehyde(MDA)],and endothelial function indicators[serum endothelin-1(ET-1),and nitric oxide(NO)].Results After treatment,the total clinical effective rate in the observation group was 95.00%(57/60),significantly higher than the control group(83.33%50/60)(P<0.05).TCM syndrome scores were decreased in both groups(P<0.05),with the scores being significantly lower in the observation group(P<0.05).Similarly,renal function indicators were decreased in both groups(P<0.05),with the indicators being significantly lower in the observation group(P<0.05).ROS and MDA levels were decreased,and SOD levels were increased in both groups(P<0.05),with these changes being more significant in the observation group(P<0.05).Additionally,ET-1 levels were decreased,and NO levels were increased in both groups(P<0.05),with these changes being more significant in the observation group(P<0.05).During treatment,the adverse reaction rate in the observation group was 5.00%(3/60),significantly lower than the control group(16.67%10/60)(P<0.05).Conclusion Suoquan Pills and Shuilu Erxian Pills combined with Western medicine can significantly improve the TCM syndrome and renal function in CGN patients with kidney qi deficiency.The mechanism may be related to antioxidant stress,endothelial function regulation,and multi-target synergistic effects,with higher safety.
作者
高琪
李星瑶
赵延红
吴喜利
GAO Qi;LI Xing-yao;ZHAO Yan-hong;WU Xi-li(Department of Traditional Chinese Medicine,The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an Shaanxi 710000)
出处
《世界中西医结合杂志》
2025年第11期2204-2210,共7页
World Journal of Integrated Traditional and Western Medicine
基金
陕西省中医药管理局中医药“双链融合”中青年科研创新团队项目(2022-SLRH-LJ-011)
陕西省中医药管理局2024年中央公共卫生发展项目(20230519-1)。
关键词
慢性肾小球肾炎
缩泉丸
水陆二仙丹
肾功能
中医证候积分
Chronic Glomerulonephritis
Suoquan Pill
Shuilu Erxian Pill
Renal Function
TCM Syndrome Score
